

Date: 02/12/2025

To,
The Listing Compliance Department
BSE Limited
Pheroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001

Scrip Code: 544611 (BSE SME)

Subject: Outcome of Board Meeting held on Tuesday, December 02, 2025 under regulation 30, 33 and other applicable provisions of SEBI (LODR) Regulations, 2015

Dear Sir/Madam,

Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable provisions, we are pleased to inform you that the Board of Directors of **Mahamaya Lifesciences Limited** at their meeting held today, i.e. **Tuesday, on December 02, 2025**, has inter-alia, considered and approved the following:

1. Unaudited Financial Results (Standalone and Consolidated) along with the Limited Review Report of the Auditors of the Company for the half-year ended September 30, 2025, as duly reviewed and recommended by the Audit Committee of the Company.

The Meeting commenced at 4:00 P.M. and concluded at 05:22 P.M.

A copy of the Financial Results along with the Limited Review Report is enclosed herewith for your reference and record.

These are also being made available on the website of the Company at www.mahamayalifesciences.com

You are requested to kindly take the above on record.

Thanking you
For Mahamaya Lifesciences Limited



Shilpi Bhardwaj
Company Secretary & Compliance Officer
Membership No.: A24444
Enclosed: a/a

Independent Auditor's Review Report on the Half year ended 30th September 2025 Unaudited Standalone Financial Results of Mahamaya Lifesciences Limited pursuant to the Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to The Board of Directors of Mahamaya Lifesciences Limited

1. We have reviewed the accompanying statement of unaudited financial results of **Mahamaya Lifesciences Limited** ('the Company') for the half year ended 30th September 2025, attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations')
2. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review
3. We conducted our review of the Statement in accordance with the **Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity'** issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free from material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33 (8) of the Regulations, to the extent applicable

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of the above matters.

For N Naresh and Co.
Chartered Accountants
Firm Registration no: 0011293S



CA Kumar E
Partner
Membership Number: 217549
UDIN:25217549BMIMVJ1448
Place: Gurugram
Date: 02.12.2025



Head Office : 27-C, Mariamman Koil Street, (Off Kamarajar Street), Villupuram - 605 602.

Chennai : No. 105, AVM Avenue 5th Street, Virugambakkam, Chennai - 600 092.

Bangalore : 23, Amarjyothi Layout, G1 Guru Nivasa Apartment, Sanjay Nagar, Bangalore - 560 094.

E-mail : ramkumarcas@gmail.com


MAHAMAYA LIFESCIENCES LIMITED
(Formerly Known as Mahamaya Lifesciences Pvt. Ltd.)

369, 370, 370A and 370B, 3rd Floor, Tower B-1,
Spaze iTech Park, Sector-49, Sohna Road
Gurugram - 122018, Haryana, India
Tel. : +91-124-4301988 / 4101430 / 4371988
E-mail : info@mahamayalifesciences.com
Web : www.mahamayalifesciences.com
CIN : U24233DL2002PLC115261

Mahamaya Lifesciences Limited
(Formerly known as Mahamaya Lifesciences Private Limited)
CIN: U24233DL2002PLC115261
Statement of Unaudited Standalone Financial Results for the Period ended 30th September 2025
(All amounts are in Indian Rupees in Lakhs, except otherwise stated)

Particulars	Half Year Ended		Year ended
	September 30,2025	September 30,2024	March 31,2025
	Unaudited	Audited	Audited
Income			
Revenue From Operations	16,306.37	14,623.12	26,414.86
Other Operating Income	32.52	5.92	160.16
Other Income	94.11	85.98	142.28
Total Income (I)	16,433.00	14,715.01	26,717.31
Expenses			
Purchases of Goods and Other Direct Expenses	17,103.14	15,732.61	27,598.00
(Increase)/ Decrease in Inventories	(3,164.62)	(3,056.81)	(4,918.35)
Employee Benefit Expenses	387.26	304.14	720.36
Finance cost	385.02	354.63	683.00
Depreciation and Amortization	109.76	77.44	177.28
Other Expenses	455.37	304.76	719.47
Total Expenses (II)	15,275.94	13,716.77	24,979.77
Profit before tax { (I) - (II) } (III)	1,157.06	998.23	1,737.54
Prior period Expenses (IV)	0.44	11.13	11.13
Profit before tax (III) - (IV)	1,156.62	987.10	1,726.41
Tax expenses			
Current Tax	282.31	249.32	407.50
Tax of earlier years	4.76	7.53	7.53
Deferred Tax	16.99	5.01	29.32
Total Tax Expenses	304.06	261.86	444.35
Profit for the year	852.56	725.25	1,282.06
Paid up Share Capital (Face value of Rs. 10 per share)	1,776.62	1,776.62	1,776.62
Total Reserves			3,210.08
Earnings per share (Rs. per share)			
Basic & Diluted (in Rs.)	4.80	4.48	7.52

For and on behalf of the Board of Directors of

Mahamaya Lifesciences Limited


Krishnamurthy Ganesan

Managing Director

DIN: 00270539

Place : Gurugram

Date : 02.12.2025

Notes :

1. The unaudited standalone financial results for the half year ended September 30, 2025 has been prepared in accordance with the Generally Accepted Accounting Principles in India (Indian GAAP) as notified under section 133 of the Companies Act, 2013 and in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and other recognised accounting principles generally accepted in India were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meeting held on December 02, 2025.
2. The Company is engaged in providing high quality and effective Agricultural Crop Protection Solutions; the main objects of the Company are to carry on the business of import, export, manufacturing, trading, marketing and consultancy of Crop Protection Products, Health care science; Health care products and Medicines.
3. The above unaudited financials results of the Company are available on the Company's website (www.mahamayalifesciences.com) and stock exchanges websites BSE (www.bseindia.com), where the shares of the Company are listed.



Mahamaya Lifesciences Limited

(Formerly known as Mahamaya Lifesciences Private Limited)


CIN: U24233DL2002PLC115261

Statement of Unaudited Standalone Balance Sheet for the Period ended 30th September 2025

(All amounts are in Indian Rupees in Lakhs, except otherwise stated)

Particulars	Half Year Ended		Year ended
	September 30,2025	September 30,2024	March 31,2025
	Unaudited	Audited	Audited
Equity and liabilities			
Shareholder's fund			
Share Capital	1,776.62	1,776.62	1,776.62
Reserves and Surplus	4,059.64	2,846.06	3,210.08
	5,836.26	4,622.68	4,986.70
Non current liabilities			
Long Term Borrowings	460.27	643.63	616.01
Long Term Provisions	46.03	40.87	43.85
Deferred Tax Liabilities (net)	87.66	46.36	70.67
	593.96	730.86	730.53
Current liabilities			
Short Term Borrowings	6,370.73	4,186.70	5,195.41
Trade Payables			
(A) Total outstanding dues of micro enterprises and small enterprises	267.43	506.97	127.21
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	7,482.09	3,526.67	5,379.59
Other Current Liabilities	349.21	525.59	691.15
Short Term Provisions	2,795.59	1,139.53	1,768.43
	17,265.05	9,885.46	13,161.78
TOTAL	23,695.27	15,239.00	18,879.01
Assets			
Non current assets			
Property, Plant and Equipment	2,106.37	1,872.88	2,173.95
Capital Work in Progress	6.00	-	-
Intangible Assets- Product Research	507.95	213.88	467.84
Intangible Assets - Pre-operative Exp. New Plant	45.35	81.65	63.55
Intangible Assets under development- Product Research	465.03	348.15	411.96
Non Current Investments	4.90	4.90	4.90
Other Non Current Assets	43.25	33.93	44.86
	3,178.85	2,555.38	3,167.06
Current assets			
Inventories	13,185.38	8,159.22	10,020.76
Trade Receivables	6,248.81	3,170.74	4,846.29
Cash and Bank Balances	419.90	572.09	399.49
Short Term Loans, Advances and Deposits	618.86	755.30	411.73
Other current assets	43.47	26.27	33.68
	20,516.42	12,683.62	15,711.95
TOTAL	23,695.27	15,239.00	18,879.01

For and on behalf of the Board of Directors of
Mahamaya Lifesciences Limited



Krishnamurthy Ganeshan
 Managing Director
 DIN: 00270539



Place : Gurugram
 Date : 02.12.2025



Mahamaya
 (Formerly Known as Mahamaya Lifesciences Pvt. Ltd.)
 369, 370, 370A and 370B, 3rd Floor, Tower B-1,
 Space ITech Park, Sector-49, Sohna Road,
 Gurugram - 122018, Haryana, India
 Tel : +91-124-4301988 / 4101430 / 4371908
 E-mail : info@mahamayalifesciences.com
 Web : www.mahamayalifesciences.com
 CIN : U24233DL2002PLC115261

MAHAMAYA LIFESCIENCES LIMITED

369, 370, 370A and 370B, 3rd Floor, Tower B-1,
 Space ITech Park, Sector-49, Sohna Road,
 Gurugram - 122018, Haryana, India
 Tel : +91-124-4301988 / 4101430 / 4371908
 E-mail : info@mahamayalifesciences.com
 Web : www.mahamayalifesciences.com
 CIN : U24233DL2002PLC115261

Mahamaya Lifesciences Limited

(Formerly known as Mahamaya Lifesciences Private Limited)

CIN: U24233DL2002PLC115261

Standalone Cash Flow Statement for the Period ended September 30, 2025

(All amounts are in Indian Rupees in Lakhs, except otherwise stated)

Particulars	Half Year Ended		Year ended
	September 30, 2025	September 30, 2024	March 31, 2025
	Unaudited	Audited	Audited
A. Cash flow from Operating activities			
Profit before tax	1,156.62	987.10	1,726.41
Adjustments for :			
Depreciation and Amortisation	109.76	77.44	180.99
Interest Expense	385.02	354.63	680.81
Profit on sale of PPE	-	-	(2.75)
Interest Income	(11.70)	(11.44)	(24.66)
Operating profit before Working Capital changes	1,639.70	1,407.73	2,560.81
Working Capital changes:			
(Increase)/ decrease in Inventories	(3,164.62)	(3,056.81)	(4,918.35)
(Increase)/ decrease in Trade Receivables	(1,402.52)	(339.86)	(2,015.41)
(Increase)/decrease in Short-term Loans, Advances and Deposits	(207.13)	(291.42)	(278.00)
(Increase)/decrease in Other Current Assets	(9.79)	(150.25)	(40.65)
(Increase)/decrease in Other Non Current Assets	(188.45)	(0.96)	(11.89)
(Decrease)/Increase in Trade Payables	2,242.72	1,767.83	3,240.98
Increase/ (decrease) in Other Current Liabilities	(341.94)	45.01	210.57
Increase/(decrease) in Provisions	742.27	700.20	1,103.02
Cash generated from / (used in) operations	(689.75)	81.48	(148.93)
Direct taxes paid (net of refunds received)	-	(256.85)	(185.95)
Net cash flow from/(used in) Operating activities	(689.75)	(175.36)	(334.89)
B. Cash flow from Investing activities			
Purchase of Property, Plant and Equipment	(70.10)	(121.40)	(504.38)
Sale of Property, Plant and Equipment	-	25.00	36.57
Interest received	11.70	11.44	24.66
Net cash flow from/(used in) Investing activities	(58.40)	(84.96)	(443.15)
C. Cash flow from Financing activities			
Interest paid	(385.02)	(354.63)	(680.81)
Fresh issue of Equity Shares	-	1,379.39	1,379.39
Issue Expenses	(3.00)	-	(192.79)
Repayment of Long term Borrowings	(155.73)	(211.18)	(200.28)
Proceeds from Short term Borrowings	1,175.33	-	1,140.82
Repayment of Short term Borrowings	-	(421.08)	(591.72)
Net cash flow from/(used in) Financing activities	631.57	392.49	854.60
Net increase in cash and Cash equivalents (A+B+C)	(116.58)	132.17	76.56
Cash and Cash equivalents at the beginning of the year	185.46	108.89	108.89
Cash and Cash equivalents as at the end of the year	68.88	241.06	185.46
Cash and Cash equivalents			
Cash in hand	52.59	18.54	38.09
With banks - Deposits with remaining maturity less than 3 months as at the Balance sheet date	-	18.55	136.99
With banks - in current accounts	16.29	203.97	10.37
Total cash and Cash equivalent at the end of the year	68.88	241.06	185.46

For and on behalf of the Board of Directors of

Mahamaya Lifesciences Limited


 Krishnamurthy Ganesan

Managing Director

DIN: 00270539

Place : Gurugram

Date : 02.12.2025



Independent Auditor's Review Report on the Half year ended 30th September 2025 Unaudited Consolidated Financial Results of Mahamaya Lifesciences Limited pursuant to the Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to The Board of Directors of Mahamaya Lifesciences Limited

1. We have reviewed the accompanying statement of unaudited financial results of **Mahamaya Lifesciences Limited** ('the Company') for the half year ended 30th September 2025. and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulations 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations')
2. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review
3. We conducted our review of the Statement in accordance with the **Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity'** issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free from material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33 (8) of the Regulations, to the extent applicable

4. The Statement includes the results of Mahamaya Lifesciences Limited (Holding Company) and Mahamaya Lifesciences (FZE) (Wholly Owned Subsidiary Company).
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



Head Office : 27-C, Mariamman Koil Street, (Off Kamarajar Street), Villupuram - 605 602.

Chennai : No. 105, AVM Avenue 5th Street, Virugambakkam, Chennai - 600 092.

Bangalore : 23, Amarjyothi Layout, G1 Guru Nivasa Apartment, Sanjay Nagar, Bangalore - 560 094.

E-mail : ramkumarcas@gmail.com

Our conclusion is not modified in respect of the above matters.

For N Naresh and Co.
Chartered Accountants
Firm Registration no: 0011293S



CA Kumar E
Partner
Membership Number: 217549
UDIN: 25217549BMIMVK8275

Place: Gurugram
Date: 02.12.2025

Mahamaya Lifesciences Limited

(Formerly known as Mahamaya Lifesciences Private Limited)

CIN: U24233DL2002PLC115261

Statement of Unaudited Consolidated Financial Results for the Period ended 30th September 2025

(All amounts are in Indian Rupees in Lakhs, except otherwise stated)

Particulars	Half Year Ended		Year ended
	September 30, 2025	September 30, 2024	March 31, 2025
	Unaudited	Audited	Audited
Income			
Revenue From Operations	16,306.37	14,623.12	26,414.86
Other Operating Income	32.52	5.92	160.16
Other Income	94.11	85.98	142.28
Total Income (I)	16,433.00	14,715.01	26,717.31
Expenses			
Purchases of Goods and Other Direct Expenses	17,103.14	15,732.61	27,598.00
(Increase)/ Decrease in Inventories	(3,164.62)	(3,056.81)	(4,918.35)
Employee Benefit Expenses	387.26	304.14	720.36
Finance cost	385.02	354.63	683.00
Depreciation and Amortization	109.76	77.44	177.28
Other Expenses	470.75	305.35	720.68
Total Expenses (II)	15,291.32	13,717.37	24,980.97
Profit before tax {I} - {II} {III}	1,141.68	997.64	1,736.33
Prior period Expenses (IV)	0.44	11.13	11.13
Profit before tax {III} - {IV}	1,141.24	986.51	1,725.20
Tax expenses			
Current Tax	282.31	249.32	407.19
Tax of earlier years	5.06	7.53	7.53
Deferred Tax	16.99	5.01	29.32
Total Tax Expenses	304.36	261.86	444.04
Profit for the year	836.88	724.65	1,281.16
Paid up Share Capital (Face value of Rs. 10 per share)	1,776.62	1,776.62	1,776.62
Total Reserves			3,165.37
Earnings per share (Rs. per share)			
Basic & Diluted	4.71	4.47	7.52

For and on behalf of the Board of Directors of

Mahamaya Lifesciences Limited



Krishnamurthy Ganesan
Managing Director
DIN: 00270539

MAHAMAYA LIFESCIENCES LIMITED

Place : Gurugram

Date : 02.12.2025

Notes :

1. The unaudited standalone financial results for the half year ended September 30, 2025 has been prepared in accordance with the Generally Accepted Accounting Principles in India (Indian GAAP) as notified under section 133 of the Companies Act, 2013 and in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and other recognised accounting principles generally accepted in India were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meeting held on December 02, 2025.
2. The Company is engaged in providing high quality and effective Agricultural Crop Protection Solutions; the main objects of the Company are to carry on the business of import, export, manufacturing, trading, marketing and consultancy of Crop Protection Products, Health care science; Health care products and Medicines.
3. The Company has incorporated a wholly owned subsidiary i.e. Mahamaya Lifesciences (FZE) with 1 equity shares of AED 150,000 situated in Sharjah, U.A.E.
4. Total capital contribution to be made in Mahamaya Lifesciences FZE, is AED 150,000/- out of which, the Company has remitted AED 10,000 in 2018 & AED 15,000 in 2019 and is planning to send the balance in FY 25-26 and complete the investment.
5. In the preparation of these Consolidated Financial Statements, investment in Subsidiary has been accounted for in accordance with Accounting Standard (AS) 21, Consolidated Financial Statements.
6. The above unaudited financial results of the Company are available on the Company's website (www.mahamayalifesciences.com) and stock exchanges websites BSE (www.bseindia.com), where the shares of the Company are listed.



Mahamaya Lifesciences Limited
 (Formerly known as Mahamaya Lifesciences Private Limited)
CIN: U24233DL2002PLC115261

Statement of Unaudited Consolidated Balance Sheet for the Period ended 30th September 2025

(All amounts are in Indian Rupees in Lakhs, except otherwise stated)

Particulars	Half Year Ended		Year ended
	September 30, 2025	September 30, 2024	March 31, 2025
	Unaudited	Audited	Audited
Equity and liabilities			
Shareholder's fund			
Share Capital	1,776.62	1,776.62	1,776.62
Reserves and Surplus	3,991.26	2,805.99	3,165.37
	5,767.88	4,582.61	4,941.99
Non current liabilities			
Long Term Borrowings	460.27	643.63	616.01
Long Term Provisions	46.03	40.87	43.85
Deferred Tax Liabilities (net)	87.66	46.36	70.67
	593.96	730.86	730.53
Current liabilities			
Short Term Borrowings	6,370.73	4,186.70	5,195.41
Trade Payables			
(A) Total outstanding dues of micro enterprises and small enterprises	267.43	506.97	127.21
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	7,482.09	3,522.52	5,379.59
Other Current Liabilities	349.21	525.59	691.15
Short Term Provisions	2,795.59	1,140.13	1,769.35
	17,265.05	9,881.90	13,162.70
TOTAL	23,626.89	15,195.37	18,835.22
Assets			
Non current assets			
Property, Plant and Equipment	2,106.37	1,872.88	2,174.12
Capital Work in Progress	6.00	-	-
Intangible Assets- Product Research	507.95	213.88	467.67
Intangible Assets - Pre-operative Exp. New Plant	45.35	81.65	63.55
Intangible Assets under development- Product Research	465.03	348.15	411.96
Other Non Current Assets	43.25	33.93	44.86
	3,173.95	2,550.48	3,162.16
Current assets			
Inventories	13,185.38	8,159.22	10,020.76
Trade Receivables	6,248.81	3,170.74	4,846.29
Cash and Bank Balance	419.90	572.09	399.49
Short Term Loans, Advances and Deposits	555.38	716.57	372.85
Other current assets	43.47	26.27	33.68
	20,452.94	12,644.89	15,673.06
TOTAL	23,626.89	15,195.37	18,835.22

For and on behalf of the Board of Directors of
Mahamaya Lifesciences Limited

Krishnamurthy Ganesan

Managing Director

DIN: 00270539



Place : Gurugram

Date : 02.12.2025

Mahamaya Lifesciences Limited

(Formerly known as Mahamaya Lifesciences Private Limited)

CIN: U24233DL2002PLC115261


Consolidated Cash Flow Statement for the Period ended September 30, 2025

(All amounts are in Indian Rupees in Lakhs, except otherwise stated)

Particulars	Half Year Ended		Year ended
	September 30,2025	September 30,2024	March 31,2025
	Unaudited	Audited	Audited
A. Cash flow from Operating activities			
Profit before tax	1,141.24	986.51	1,725.20
Adjustments for :			
Depreciation and Amortisation	109.76	77.44	180.99
Interest Expense	385.02	354.63	680.81
Profit on sale of PPE	-	-	(2.75)
Interest Income	(11.70)	(11.44)	(24.66)
Operating profit before Working Capital changes	1,624.32	1,407.13	2,559.60
Working Capital changes:			
(Increase)/ decrease in Inventories	(3,164.62)	(3,056.81)	(4,918.35)
(Increase)/ decrease in Trade Receivables	(1,402.52)	(339.86)	(2,015.41)
(Increase)/decrease in Short-term Loans, Advances and Deposits	(182.53)	(286.65)	(273.07)
(Increase)/decrease in Other Current Assets	(9.79)	(150.25)	(40.65)
(Increase)/decrease in Other Non Current Assets	(188.45)	(0.96)	(11.89)
(Decrease)/Increase in Trade Payables	2,242.72	1,763.67	3,240.98
Increase/ (decrease) in Other Current Liabilities	(341.94)	45.01	210.57
Increase/(decrease) in Provisions	741.05	700.20	1,103.65
Cash generated from /used in operations	(681.75)	81.50	(144.58)
Direct taxes paid (net of refunds received)	-	(256.85)	(185.95)
Net cash flow from/(used in) Operating activities	(681.75)	(175.35)	(330.54)
Cash flow from Investing activities			
Purchase of Property, Plant and Equipment	(70.10)	(121.40)	(504.38)
Sale of Property, Plant and Equipment	-	25.00	36.57
Interest received	11.70	11.44	24.66
Unrealised gain/ (loss) from Translation of Foreign subsidiaries	(7.99)	(0.02)	(4.35)
Net cash flow from/(used in) Investing activities	(66.39)	(84.98)	(447.50)
Cash flow from Financing activities			
Interest paid	(385.02)	(354.63)	(680.81)
Fresh issue of Equity Shares	-	1,379.39	1,379.39
Issue Expenses	(3.00)	-	(192.79)
Repayment of Long term Borrowings	(155.73)	(211.18)	(200.28)
Proceeds from Short term Borrowings	1,175.33	-	1,140.82
Repayment of Short term Borrowings	-	(421.08)	(591.72)
Net cash flow from/(used in) Financing activities	631.57	392.49	854.60
Net increase in cash and Cash equivalents (A+B+C)	(116.58)	132.17	76.56
Cash and Cash equivalents at the beginning of the year	185.46	108.89	108.89
Cash and Cash equivalents as at the end of the year	68.88	241.06	185.46
Cash and Cash equivalents			
Cash in hand	52.59	18.54	38.09
With banks - Deposits with remaining maturity less than 3 months as at the Balance sheet date	-	18.55	136.99
With banks - in current accounts	16.29	203.97	10.37
Total cash and Cash equivalent at the end of the year	68.88	241.06	185.46

For and on behalf of the Board of Directors of

Mahamaya Lifesciences Limited


Krishnamurthy Ganesan
Managing Director
DIN: 00270539

Place : Gurugram

Date : 02.12.2025